Biocept

Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample. The company utilizes cell enrichment and extraction technology for the detection and analysis of circulating tumor DNA tests. It also offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies and clinical trial support and specific oncogenic alterations. Biocept was founded on May 12, 1997 and is headquartered in San Diego, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q1 2024

Biocept, Inc. is an oncology laboratory service company, which engages in the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. The company was founded on May 12, 1997 and is headquartered in San Diego, CA.

Biocept Inc (NASDAQ:BIOC) has reported unaudited net revenue of $61.2 million for the financial year ending December 31, 2021.  The company also said that it had cash and cash equivalents of about $28 million as of December 31, 2021 as it develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers.

Biocept reports unaudited net revenue of $61.2 million for 2021

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports unaudited net revenue for 2021 of $61.2 million and cash and cash equivalents as of December 31, 2021 of approximately $28 million. “Revenue reached a record high in 2021, up 123% over the prior year driven primarily by RT-PCR COVID-19 testing. As anticipated, we are currently experiencing a decline in COVID-19 testing demand as the unpredictable pandemic b

Biocept Reports Unaudited 2021 Revenue and Year-End Cash Balance

SAN DIEGO--(BUSINESS WIRE)---- $BIOC--Biocept to report 2021 fourth quarter and full year financial results on March 30, 2022.

Biocept to Report 2021 Fourth Quarter and Full Year Financial Results on March 31, 2022

SAN DIEGO--(BUSINESS WIRE)--Biocept names Philippe Marchand as new Chief Operating Officer to oversee strategic business operations, including its CNSide CSF assay.

Biocept Appoints Philippe Marchand as Chief Operating Officer

Biocept Inc (NASDAQ:BIOC) (Biocept Inc (NASDAQ:BIOC)) has highlighted how its CNSide cerebrospinal fluid (CSF) assay could improve the treatment options for brain cancer patients. The biotech has been presenting at the Molecular & Precision Med Tri-Con meeting— the leading international meeting for the precision medicine community—being held in San Diego between February 21 and 23 this year.

Biocept outlines how its CNSide cerebrospinal fluid assay could improve treatment options for brain cancers

SAN DIEGO--(BUSINESS WIRE)--Biocept highlights CNSide assay's ability to aid clinical research efforts to improve treatment of metastatic cancers involving brain.

Biocept Presentation at Molecular Medicine Tri-Con Meeting Highlights Potential of CNSide™ Assay to Support Development of Targeted Therapies for Metastatic Brain Cancer

Biocept Inc (NASDAQ:BIOC) announced the appointments of Samuel Riccitelli as the company's new interim CEO as well as Antonino Morales as its interim chief financial officer (CFO). Biocept also said it named M.

Biocept appoints Samuel Riccitelli as its interim CEO and Antonino Morales as interim CFO

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointments of Samuel D. Riccitelli as Interim President and Chief Executive Officer, succeeding Michael W. Nall, and Antonino Morales as Interim Chief Financial Officer, succeeding Timothy C. Kennedy. Biocept also named M. Faye Wilson as Lead Independent Director of the company's Board of Directors. Mr. Riccitelli remains Chair of the Board. “I am g

Biocept Appoints Samuel D. Riccitelli as Interim President and Chief Executive Officer and Antonino Morales as Interim Chief Financial Officer

Biocept Inc (NASDAQ:BIOC) announced that it has appointed Darrell Taylor as the company's new senior vice president, general counsel and chief compliance officer.  Biocept said Taylor will lead essential aspects of legal, compliance and privacy efforts, and will report to company CEO Michael Nall.

Biocept appoints Darrell Taylor as its new chief compliance officer

SAN DIEGO--(BUSINESS WIRE)--Biocept names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer.

Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer

Biocept Inc (NASDAQ:BIOC) announced that coronavirus (COVID-19) RT-PCR testing volume has increased in 2022 with the emergence of the Omicron variant.  The San Diego-based company said that it continues to serve the community with high-quality testing, having received more than 40,000 samples for COVID-19 testing since the beginning of 2022 and more than 765,000 samples since initiating this service in June 2020.

Biocept says demand for its COVID-19 RT-PCR testing increases in 2022 amid Omicron variant surge

SAN DIEGO--(BUSINESS WIRE)---- $BIOC #CLIA_Lab--Biocept has received more than 765,000 samples for RT-PCR COVID-19 testing since June 2020.

Biocept Reports an Increase in COVID-19 RT-PCR Testing Volume with Spread of the Omicron Variant

Here is how Biocept, Inc. (BIOC) and BioVie Inc. (BIVI) have performed compared to their sector so far this year.

Has Biocept, Inc. (BIOC) Outpaced Other Medical Stocks This Year?

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022. A webcast of the Biocept presentation can be accessed on the Investor Relations section of the company website beginning on January 10, 2022 at 7:00 a.m. Eastern time. “Our priority in 2022 is to contin

Biocept to Present at the H.C. Wainwright BioConnect Virtual Conference on January 10

Biocept Inc (NASDAQ:BIOC) said it presented a study demonstrating the ability of its CNSide assay to identify HER2 and other actionable tumor alterations in the cerebrospinal fluid of patients with breast cancer and leptomeningeal disease (LMD).  The poster was chosen for a Spotlight Presentation at the San Antonio Breast Cancer Symposium on December 8, 2021, the company added in a statement.

Biocept says its CNSide assay identified HER2 and other tumor alterations in cerebrospinal fluid of patients with breast cancer and leptomeningeal disease

SAN DIEGO--(BUSINESS WIRE)--SABCS Spotlight Presentation shows that Biocept's CNSide CSF assay identifies actionable HER2 mutations in metastatic breast cancer.

Biocept's CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that has Metastasized to the Brain

Quest Diagnostics

SECAUCUS, N.J. and SAN DIEGO, Dec. 1, 2021 /PRNewswire/ -- Physicians in the United States can now order the liquid biopsy-based Target Selector™ NGS Lung Panel test directly from Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services.

Quest Diagnostics Now Offers Biocept's Liquid Biopsy Test for Lung Cancer, Expanding its Menu of Advanced Cancer Diagnostics

Biocept Inc (NASDAQ:BIOC) said that it has started offering a single test that can detect and distinguish between SARS-CoV-2 and influenza, helping patients and caregivers determine appropriate treatment decisions.  This new assay expands the company's coronavirus (COVID-19) testing program, which began in June 2020 and has now received more than 670,000 samples for processing.

Biocept launches single test for COVID-19 and Influenza as cases rise during flu season

SAN DIEGO--(BUSINESS WIRE)--Biocept launches combined COVID-19 and influenza test to help patients and caregivers determine treatment decisions during peak flu season.

Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season

SAN DIEGO--(BUSINESS WIRE)--Case series shows Biocept's CNSide assay helps monitor treatment response and detects actionable biomarkers in patients with metastatic breast cancer.

CORRECTING and REPLACING Biocept's CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast Cancer

Biocept Inc (NASDAQ:BIOC) will present a multi-institutional case series on its CNSide cerebrospinal fluid assay at the upcoming Society for Neuro-Oncology annual meeting in Boston. The San Diego-based biotech company said it will show how CNSide helps physicians monitor treatment response and detects actionable mutations in patients with metastatic breast cancer and leptomeningeal disease (LMD).

Biocept to present latest findings on CNSide cerebrospinal fluid assay and its use in treating breast cancer complications at Society for Neuro-Oncology annual meeting

Biocept's CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast Cancer

Patented liquid biopsy technology called Target Selector detects cancer biomarkers Ramping up global marketing efforts for its blood tests and related products to grow organically Has received to date more than 250,000 coronavirus test samples at its San Diego lab What Biocept does: Biocept Inc (NASDAQ:BIOC) is a molecular diagnostics company focused on changing the way physicians examine blood in their patients with cancer. The San Diego-based company sells CEE-Sure blood collection tubes and has developed a patented liquid biopsy technology called Target Selector that detects and isolates cancer biomarkers such as circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA).

Biocept is changing the way physicians examine blood work for their cancer patients and doing coronavirus testing

Biocept Inc (NASDAQ:BIOC), the diagnostics-focused group, swung to a profit in its third quarter, recovering from the loss it reported in the corresponding period last year, thanks to a 165% increase in revenue on the back of increased RT-PCR COVID-19 testing. For the three months to September 30, the company posted net income of $427,000 compared to a loss of $4.9 million in 3Q, 2020.

Biocept sees profitability in third quarter thanks to increased RT-PCR COVID-19 testing

Biocept, Inc. (BIOC) CEO Michael Nall on Q3 2021 Results - Earnings Call Transcript

News for Biocept Stock (BIOC)